Compositions for a dietary supplement to manage senescent cells
US-2024390346-A1 · Nov 28, 2024 · US
SGLT1/2 inhibitor LIK066 for treating obesity
US10952989B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10952989-B2 |
| Application number | US-201816490554-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 2, 2018 |
| Priority date | Mar 3, 2017 |
| Publication date | Mar 23, 2021 |
| Grant date | Mar 23, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is drawn to methods for effecting weight loss, e.g. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating obesity, comprising administering to a patient in need, a dosage of about 1-50 mg of LIK066, or salt thereof; wherein said patient has a body mass index of at least 25 kg/m 2 . 2. The method according to claim 1 , wherein the dosage is selected from the group consisting of 2.5 mg, 5 mg, 10 mg, 25 mg, 35 mg, and 50 mg. 3. The method according to claim 1 , wherein the dosage is about 35 mg. 4. The method according to claim 1 , wherein the dosage is about 50 mg. 5. The method of claim 1 , wherein said LIK066 or salt thereof is formulated for oral administration. 6. The method according to claim 1 , wherein the dosage is administered once a day. 7. The method according to claim 1 , wherein the dosage is administered twice a day. 8. The method of claim 1 , wherein said patient has a condition associated with obesity selected from high blood pressure, high levels of triglycerides, elevated fasting blood glucose and diabetes. 9. The method of claim 1 , wherein said patient has a body mass index of at least 30 kg/m 2 . 10. The method of claim 1 , comprising a reduction of at least about 5% of body weight. 11. A method of treating obesity, comprising administering to a patient, a dosage of about 35-50 mg of LIK066 or a salt thereof once or twice daily; wherein said patient has a body mass index of at least 25 kg/m 2 . 12. The method of claim 11 , comprising administering about 50 mg of LIK066 or a salt thereof. 13. The method of claim 11 , wherein said patient has a condition associated with obesity selected from high blood pressure, high levels of triglycerides, elevated fasting blood glucose and diabetes. 14. The method of claim 11 , wherein said patient has a body mass index of at least 30 kg/m 2 . 15. The method of claim 11 , comprising a reduction of at least about 5% of body weight.
Assignees
Inventors
Classifications
- A61K31/357Primary
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Anorexiants; Antiobesity agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10952989B2 cover?
- The present invention is drawn to methods for effecting weight loss, e.g. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/357. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).